Fusion Antibodies plc (AIM: FAB), as the Early Discovery Contract Research Organisation specialising in pre-clinical antibody discovery, announces its unaudited interim results for the six months ended 30 September 2023
ValiRx PLC (AIM:VAL) Agreement to License VAL401 to Ambrose Healthcare
ValiRx Plc (AIM: VAL), a life science company focusing on cancer therapeutics and women’s health, announces that ValiSeek Limited (“ValiSeek”), has entered into an exclusive Option Agreement to license VAL401
BSF Enterprise PLC (LON:BSFA) 3D Bio-Tissues Product Partnership Progress
BSF (LSE: BSFA), (OTCQB: BSFAF), the Main Market listed biotech company and owner of pioneering UK-based clinical and cellular agriculture company 3D Bio-Tissues (3DBT), provides an update on the Company’s partnership progress
RUA Life Sciences (AIM:RUA) Trading Update
Half-Year Trading Update
Poolbeg Pharma PLC (AIM:POLB) Immunomodulator II patent granted in Japan
Further enhancement of the patent portfolio
AstraZeneca enhances its earnings amid the emergence of legal proceedings related to vaccines.
AstraZeneca surpassed profitability expectations as it disclosed its third-quarter earnings, even as it confronts a significant legal challenge alleging that the effectiveness of its vaccines was greatly exaggerated.
Poolbeg Pharma PLC (AIM:POLB) Former Amryt Pharma Leadership Team join Poolbeg
Key Senior Members of Former Amryt Pharma Leadership Team join Poolbeg Pharma Poolbeg team boosted by highly experienced executives with track record of success
Poolbeg Pharma plc (AIM:POLB) POLB 001 Data to be Presented at American Society of Hematology Annual Meeting
Potential to address cancer treatment-related Cytokine Release Syndrome
Poolbeg Pharma PLC (AIM:POLB) POLB 001 Oncology Programme Update Meeting
1 November 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that it will host a meeting for investors
Poolbeg Pharma PLC – SAB Endorses Influenza Drug Targets
Scientific Advisory Board Endorses Influenza Drug Targets Identified in AI Drug Discovery Programme
Abingdon Health PLC (AIM:ABDX) Final Results
York, U.K. 17 October 2023: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract research (CRO) and contract development and manufacturing organisation (CDMO), announces its final results for the